Phase 2 Trial of SC Versus IV Anakinra to Prevent CRS and Neurotoxicity in LBCL Patients Receiving Lisocabtagene Maraleucel: Final Analysis and Comparison to Historical Control
Emily C. Liang(Fred Hutch Cancer Center), Jordan Gauthier(Seattle Cancer Care Alliance), Yein Jeon(University of Washington), Ryan Basom(Fred Hutch Cancer Center), Tony Chour(University of Washington), Erik L. Kimble(University of Washington), Delaney R. Kirchmeier(Fred Hutch Cancer Center), Aiko Torkelson(Fred Hutch Cancer Center), Qian Wu(Cancer Research Center), Andrew J. Portuguese(University of Washington), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Mazyar Shadman(University of Washington), Filippo Milano(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Evan W. Newell(Agency for Science, Technology and Research), Folashade Otegbeye(University Hospitals of Cleveland), Aya Albittar(University of Washington), Ryan D. Cassaday(University of Washington), Cameron J. Turtle(The University of Sydney), Nikki Pin(Fred Hutch Cancer Center), Jennifer J. Huang(Stanford Medicine), Barbara S. Pender, Kristina Braathen(Fred Hutch Cancer Center), Kent Kito(Fred Hutch Cancer Center), Ismat Jahan(Fred Hutch Cancer Center), Shelby Colden(Fred Hutch Cancer Center), Koko Abe(Fred Hutch Cancer Center), Sylvain Simon(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Gina Simmons(Fred Hutch Cancer Center), Valentin Ortiz-Maldonado(Hospital Clínic de Barcelona)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795